Galapagos to present at 39th Annual J.P. Morgan Healthcare Conference
January 06 2021 - 9:30AM
Mechelen, Belgium; 6 January 2021, 15.30 CET – Galapagos
NV (Euronext & NASDAQ: GLPG) will participate in the 39th
Annual J.P. Morgan Healthcare Conference on January 11-14,
2021.
Onno van de Stolpe, CEO, will present on
Thursday, January 14 at 15.10 CET (09:10 am EST). The presentation
will be a live audio webcast and can be accessed via the following
link. A replay of the webcast will be available on the Galapagos’
website at www.glpg.com.
About GalapagosGalapagos NV
discovers and develops small molecule medicines with novel modes of
action, several of which show promising patient results and are
currently in late-stage development in multiple diseases. Our
pipeline comprises discovery through Phase 3 programs in
inflammation, fibrosis and other indications. Our ambition is to
become a leading global biopharmaceutical company focused on the
discovery, development and commercialization of innovative
medicines. More information at www.glpg.com.
Contacts
Investors:Elizabeth GoodwinVP Investor
Relations +1 781 460 1784
Sofie Van GijselSenior Director Investor Relations+32 485 19 14
15ir@glpg.com
Media:Carmen VroonenGlobal Head Communications
& Public Affairs+32 473 824 874
Anna GibbinsSenior Director Therapeutic Areas Communications+44
7717 801900
communications@glpg.com
Forward-looking statements
This press release includes forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, that are subject to risks,
uncertainties and other factors that could cause actual results to
differ materially from those referred to in the forward-looking
statements and, therefore, the reader should not place undue
reliance on them. These risks, uncertainties and other factors
include, without limitation, the risk that ongoing and future
clinical studies with Galapagos’ compounds may not be completed in
the currently envisaged timelines or at all, the inherent
uncertainties associated with competitive developments, clinical
trial and product development activities and regulatory approval
requirements (including that data from the ongoing and planned
clinical research programs may not support registration or further
development of Galapagos’ compounds due to safety, efficacy or
other reasons), Galapagos' reliance on collaborations with third
parties and that Galapagos’ estimations regarding its compounds
development program and regarding the commercial potential of
Galapagos’ compounds, may be incorrect, as well as those risks and
uncertainties identified in our Annual Report on Form 20-F for the
year ended 31 December 2019 and our subsequent filings with the
SEC. All statements other than statements of historical fact are
statements that could be deemed forward-looking statements. The
forward-looking statements contained herein are based on
management’s current expectations and beliefs and speak only as of
the date hereof, and Galapagos makes no commitment to update or
publicly release any revisions to forward-looking statements in
order to reflect new information or subsequent events,
circumstances or changes in expectations.
- Galapagos to present at 39th Annual J.P. Morgan Healthcare
Conference
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024